The short answer
Vitamin D status may merit attention during prolonged rifampin treatment, especially if your intake or baseline stores are low. Research findings vary, so rifampin does not automatically require a fixed vitamin D supplement dose.
What this answer covers
Vitamin D nutritional intake and measured status; D2/D3 preparation and existing deficiency considered individually.
- Supplement or preparation
- Vitamin D
- Medication ingredient
- rifampin
Rifampin can change vitamin D metabolism
The label notes altered vitamin D metabolism. A short rifampicin study found lower25-hydroxyvitamin D while other hormone markers remained unchanged. A laboratory change alone does not establish symptomatic deficiency.
Longer studies were less consistent
Small and larger studies of rifampicin with isoniazid did not find a uniform clinically important disturbance. Nutritional background and use of both drugs limit attribution to rifampin alone.
Focus on nutritional risk and duration
The concern is more relevant when vitamin D stores are already marginal, treatment is prolonged or symptoms suggest bone disease. The evidence does not establish that every patient needs extra vitamin D or a higher dose.
Plan assessment with the TB team
Discuss diet, existing supplements and any bone pain or muscle weakness. The clinician can decide whether testing or replacement is appropriate. No special vitamin D spacing interval was established by these studies.
Evidence and practical considerations
Timing & monitoring
Conditional adequacy/status assessment in prolonged therapy or nutritional risk, supported by label and variable human biochemical findings. Long-term combined-regimen nulls retained; no universal deficiency, dose or spacing requirement.
- Exact scope
- Vitamin D nutritional intake and measured status; D2/D3 preparation and existing deficiency considered individually. with Rifampin oral capsules and intravenous product in the combined RIFADIN label; antacid absorption warnings apply to oral dosing.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: People prescribed rifampin
Oral antacid precaution specifies rifampin at least1 hour before antacids. Enzyme induction may alter vitamin D metabolism; does not establish deficiency in everyone.
How this applies: Exact rifampin RxCUI 9384 IN, with stated salt/formulation/route bridge.
Exact route and formulation apply. Label precautions do not quantify untested botanical pairs or support arbitrary supplement doses.
Source 2: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Eight male subjects.
25-hydroxyvitamin D fell around70%, while1,25-dihydroxyvitamin D, parathyroid hormone and calcitonin did not change.
How this applies: Short study and biochemical marker, not clinical deficiency or universal supplementation requirement.
Short study and biochemical marker, not clinical deficiency or universal supplementation requirement.
Source 3: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Eight TB patients.
No significant uniform change in25-hydroxyvitamin D,1,25-dihydroxyvitamin D or other measured biochemistry.
How this applies: Small combined-drug study cannot isolate rifampin; null does not exclude susceptible patients.
Small combined-drug study cannot isolate rifampin; null does not exclude susceptible patients.
Source 4: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: 83 TB patients.
Osteomalacia prevalence was not clearly higher than background; serum calcium did not significantly change in the paired subgroup.
How this applies: Mixed regimen, baseline nutritional differences; does not establish rifampin alone caused osteomalacia.
Mixed regimen, baseline nutritional differences; does not establish rifampin alone caused osteomalacia.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Editorial update | |
| Corrected missing spaces between numbers and units or words in the copy before registration; evidence and conclusions unchanged. | |
| Article prepared | |
| Prepared exact rifampin article with formulation-specific evidence and uncertainty. |
Article revision: 66f856e157ff6162
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.